MARKSANS PHARMA LIMITED [formerly Tasc Pharmaceuticals Ltd.] Regd. Office: 601-622, Chintamani Plaza, Mohan Studio Compd, A.K.Road, Andheri [East], Mumbai-400099 AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2006

(Rs. In lacs)

		Nine Months	Quarter Ended		Year Ended	
		ended 31-12-2005	(Unaudited)		(Audited)	
Sr. No.	PARTICULARS	(Audited)	31.03.2006	31.03.2005	31.03.2006	31.03.2005
1	Net sales /Income from Operations	24,683.35	4,502.10	7,909.72	29,185.45	24,635.01
2	Other Income	212.29	258.88	55.91	471.17	163.65
3	Total Expenditure	20,497.10	4,188.26	6,545.51	24,685.36	20,454.70
	-Increase /Decrease in Stock in trade	(814.33)	(1,541.11)	(615.37)	(2,355.44)	(1,396.74)
	-Raw Material cost	18,030.16	4,618.21	6,413.75	22,648.37	18,289.17
	-Staff Cost	586.46	360.65	122.76	947.11	646.34
	-Other Expenditure	2,694.81	750.51	624.37	3,445.32	2,915.93
4	Interest	801.79	233.29	379.88	1,035.08	1,163.15
5	Depreciation	697.34	106.64	228.01	803.98	694.48
6	Profit before Tax	2,899.41	232.79	812.23	3,132.20	2,486.33
7	Provision for Taxation	596.00	218.24	311.36	814.24	445.77
8	Net Profit	2,303.41	14.55	500.87	2,317.96	2,040.56
9	Add/Less :Short provision/	29.53	-	-	29.53	-
	Prior period expenses	-	-	-		-
10	Net Profit after extra ordinary items	2,273.88	14.55	500.87	2,288.43	2,040.56
11	Paid up Equity Share Capital					
	(Face value Rs. 10 per share)	3,594.06	3,594.06	3,594.06	3,594.06	3,594.06
12	Reserves and Surplus					5,286.46
	(Excluding Revaluation Reserve)					
13	Basic and Diluted EPS for the period	6.33	0.04	1.39	6.37	5.68
	(Not annualised)					
14	Non -Promoter share holding					
	-Number of Shares	18575527	18778569	8738000	18778569	8738000
	-Percentage of Share holding	51.68%	52.25%	69.90%	52.25%	69.90%

Notes

The above results were taken on records at the Board meeting held on 29-06-2006

Provision for Taxation includes current tax, deferred tax and fringe benefit tax.

EPS of the company is calculated on weighted average number of equity shares.

The details of investor complaints during the quarter is as under:

Opening Balance: NIL, Received during the quarter: 5, Pending as on 31.03.06: NIL

Previous year's figures have been re-grouped/re-classified, whereever necessary, so as to make them comparable with the current year's figures.

For Marksans Pharma Limited

Place: Mumbai

Date: June 29, 2006 Mark Saldanha
Managing Director